Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 40 articles:
HTML format

Single Articles

    November 2022
  1. TRAN PT, Lowe K, Tsai HL, Song DY, et al
    Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
    J Clin Oncol. 2022 Nov 11:JCO2201662. doi: 10.1200/JCO.22.01662.
    PubMed     Abstract available

    October 2022
  2. MA TM, Sun Y, Malone S, Roach M 3rd, et al
    Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
    J Clin Oncol. 2022 Oct 21:JCO2200970. doi: 10.1200/JCO.22.00970.
    PubMed     Abstract available

  3. KIM JW, McKay RR, Radke MR, Zhao S, et al
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947.
    PubMed     Abstract available

    September 2022
  4. EPSTEIN JI, Kibel AS
    Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care.
    J Clin Oncol. 2022;40:3106-3109.

  5. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation.
    J Clin Oncol. 2022 Sep 16:JCO2201865. doi: 10.1200/JCO.22.01865.
    PubMed     Abstract available

    August 2022
  6. DEEK MP, Van der Eecken K, Sutera P, Deek RA, et al
    Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
    J Clin Oncol. 2022 Aug 24:JCO2200644. doi: 10.1200/JCO.22.00644.
    PubMed     Abstract available

  7. SUN R, Wei LJ
    Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Aug 19:JCO2201084. doi: 10.1200/JCO.22.01084.

    July 2022
  8. TISSEVERASINGHE S, Tolba M, Saad F, Gravis G, et al
    Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
    J Clin Oncol. 2022 Jul 21:JCO2200883. doi: 10.1200/JCO.22.00883.

    June 2022
  9. JACKSON WC, Tang M, Schipper MJ, Sandler HM, et al
    Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
    J Clin Oncol. 2022 Jun 23:JCO2102741. doi: 10.1200/JCO.21.02741.
    PubMed     Abstract available

  10. KARTOLO A, Tannock IF, Vera Badillo FE
    Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    J Clin Oncol. 2022 Jun 20:JCO2200705. doi: 10.1200/JCO.22.00705.

  11. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
    With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.

  12. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available

    May 2022
  13. CAO Y, Deville C Jr
    Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough.
    J Clin Oncol. 2022 May 23:JCO2200645. doi: 10.1200/JCO.22.00645.

    April 2022
  14. AGARWAL N, Tangen CM, Hussain MHA, Gupta S, et al
    Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
    J Clin Oncol. 2022 Apr 21:JCO2102517. doi: 10.1200/JCO.21.02517.
    PubMed     Abstract available

  15. HUSSAIN M, Carducci MA, Clarke N, Fenton SE, et al
    Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    J Clin Oncol. 2022 Apr 19:JCO2200208. doi: 10.1200/JCO.22.00208.

  16. EGGENER SE, Berlin A, Vickers AJ, Paner GP, et al
    Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
    J Clin Oncol. 2022 Apr 18:JCO2200123. doi: 10.1200/JCO.22.00123.

  17. ARMSTRONG AJ, Azad AA, Iguchi T, Szmulewitz RZ, et al
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200193. doi: 10.1200/JCO.22.00193.
    PubMed     Abstract available

    March 2022
  18. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2022 Mar 15:JCO2102800. doi: 10.1200/JCO.21.02800.
    PubMed     Abstract available

    February 2022
  19. PATEL NA, Reiter RE
    Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    J Clin Oncol. 2022 Feb 24:JCO2102940. doi: 10.1200/JCO.21.02940.

  20. VAN WAMBEKE S, Vera-Badillo FE, Gyawali B
    Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
    J Clin Oncol. 2022 Feb 21:JCO2102304. doi: 10.1200/JCO.21.02304.

    January 2022
  21. SCHODER H, Hope TA, Knopp M, Kelly WK, et al
    Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
    J Clin Oncol. 2022 Jan 11:JCO2102440. doi: 10.1200/JCO.21.02440.
    PubMed     Abstract available

  22. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    PubMed     Abstract available

  23. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.

    December 2021
  24. STOCKLER MR, Martin AJ, Davis ID, Dhillon HM, et al
    Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    J Clin Oncol. 2021 Dec 20:JCO2100941. doi: 10.1200/JCO.21.00941.
    PubMed     Abstract available

    November 2021
  25. RUSH HL, Murphy L, Morgans AK, Clarke NW, et al
    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    J Clin Oncol. 2021 Nov 10:JCO2100728. doi: 10.1200/JCO.21.00728.
    PubMed     Abstract available

  26. SADA YH
    A Dozen Eggs.
    J Clin Oncol. 2021;39:3645-3646.

    September 2021
  27. KERKMEIJER LGW, Pos FJ, Haustermans K, van der Heide UA, et al
    Reply to I. R. Vogelius et al.
    J Clin Oncol. 2021;39:3086-3087.

    July 2021
  28. BOLLA M, Neven A, Maingon P, Carrie C, et al
    Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
    J Clin Oncol. 2021 Jul 26:JCO2100855. doi: 10.1200/JCO.21.00855.
    PubMed     Abstract available

  29. SPERGER JM, Emamekhoo H, McKay RR, Stahlfeld CN, et al
    Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Jul 1:JCO2100169. doi: 10.1200/JCO.21.00169.
    PubMed     Abstract available

  30. D'AMICO AV, Xie W, McMahon E, Loffredo M, et al
    Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    J Clin Oncol. 2021 Jul 1:JCO2100596. doi: 10.1200/JCO.21.00596.
    PubMed     Abstract available

    June 2021
  31. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.

  32. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.

  33. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.

  34. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.

  35. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    PubMed     Abstract available

    May 2021
  36. TEWARI AK, Gillessen S, Sweeney CJ
    Metastatic Prostate Cancer: In Search of More Granularity.
    J Clin Oncol. 2021 May 14:JCO2100643. doi: 10.1200/JCO.21.00643.

    April 2021
  37. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.

  38. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed     Abstract available

  39. MURPHY AB, Abern MR, Liu L, Wang H, et al
    Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    J Clin Oncol. 2021 Apr 9:JCO2002997. doi: 10.1200/JCO.20.02997.
    PubMed     Abstract available

    January 2021
  40. SPRATT DE, Malone S, Roy S, Grimes S, et al
    Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
    J Clin Oncol. 2021;39:136-144.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.